Celecoxib

Generic Name: Celecoxib

Brand Names: Celebrex, Elyxyb, Seglentis

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₄F_₃N_₃O_₂S

CAS Number: 169590-42-5

Unique Ingredient Identifier: JCX84Q7J1L

Background: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.

Indication: Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.

It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.

Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.

Associated Conditions: Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain

Associated Therapies: -

Clinical Trials

A Clinical Trial of YH23537 in Patients With Knee Osteoarthritis

Phase 2

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: YH23537
Drug: YH23537 placebo
Drug: Celecoxib

First Posted Date: 2016-05-03

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 456

Registration Number: NCT02759198

Locations: 🇰🇷
KyungHee University Medical Center, Seoul, Korea, Republic of

NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis

Phase 4

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: Golimumab
Drug: Celecoxib

First Posted Date: 2016-05-02

Last Posted Date: 2021-01-27

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 156

Registration Number: NCT02758782

Locations: 🇩🇪
Rheumapraxis Kupka, Altenburg, Germany
🇩🇪
Rheumapraxis Bayreuth Dr. Ochs, Bayreuth, Germany
🇩🇪
Charite Universitaetsmedizin - Dpt. Rheumatology at Campus Charite Mitte, Berlin, Germany

and more 16 locations

Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma

Phase 2

Conditions: Oral Squamous Cell Carcinoma

Interventions: Drug: Celecoxib

First Posted Date: 2016-04-15

Last Posted Date: 2016-04-15

Lead Sponsor: China Medical University Hospital

Target Recruit Count: 270

Registration Number: NCT02739204

Locations: 🇨🇳
Department of Otolaryngology, Taichung, Taiwan

MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty

Phase 4

Completed

Conditions: Stiffness Following Total Knee Arthroplasty

Interventions: Drug: Dexamethasone
Drug: Celecoxib

First Posted Date: 2016-04-14

Last Posted Date: 2023-11-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 130

Registration Number: NCT02739035

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Hospital for Joint Diseases, New York, New York, United States

and more 13 locations

Tramadol Versus Celecoxib for Reducing Pain During Operative Office Hysteroscopy

Phase 3

Conditions: Hysteroscopy

Interventions: Drug: Celecoxib
Drug: Tramadol
Drug: Placebo 1
Drug: Placebo 2

First Posted Date: 2016-04-13

Last Posted Date: 2016-07-06

Lead Sponsor: Cairo University

Target Recruit Count: 210

Registration Number: NCT02736071

Locations: 🇪🇬
Cairo University Hospitals, Cairo, Egypt

Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women

Phase 3

Conditions: Hysteroscopy

Interventions: Drug: Celecoxib
Drug: Placebo 1
Drug: Tramadol
Drug: Placebo 2

First Posted Date: 2016-04-13

Last Posted Date: 2016-07-06

Lead Sponsor: Cairo University

Target Recruit Count: 210

Registration Number: NCT02736019

Locations: 🇪🇬
Cairo University Hospitals, Cairo, Egypt

Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression

Phase 3

Terminated

Conditions: Bipolar Disorder
Postpartum Depression

Interventions: Drug: Celecoxib
Drug: Placebo

First Posted Date: 2016-04-04

Last Posted Date: 2022-01-20

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 1

Registration Number: NCT02726659

Locations: 🇨🇦
Parkwood Institute, Mental Health Care Buildling, London, Ontario, Canada

Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain

Phase 3

Completed

Conditions: Low Back Pain

Interventions: Biological: Tanezumab 10 mg
Biological: Tanezumab 5 mg
Drug: Celecoxib
Biological: Placebo for tanezumab
Drug: Placebo for celecoxib

First Posted Date: 2016-04-01

Last Posted Date: 2020-08-11

Lead Sponsor: Pfizer

Target Recruit Count: 277

Registration Number: NCT02725411

Locations: 🇯🇵
Meitoh Hospital, Nagoya, Aichi, Japan
🇯🇵
Asahi General Hospital, Asahi, Chiba, Japan
🇯🇵
Fukuoka Mirai Hospital, Higashi-ku,Fukuoka, Fukuoka, Japan

and more 52 locations